GoodRx Holdings Inc (GDRX) reports robust growth in adjusted EBITDA and Pharma Manufacturer Solutions revenue, despite facing ...

Over the past few days, the news from GoodRx Holdings (NASDAQ: GDRX) hasn't been all that good. On Thursday the online ...

GoodRx (NASDAQ: GDRX) Q3 2024 Earnings Call Nov 07, 2024, 8:00 a.m. ET ...

GoodRx (NASDAQ:GDRX – Get Free Report) had its price target lowered by Barclays from $10.00 to $6.00 in a research note ...

The matter is relevant to the pharmacies as GoodRx markets a prescription drug discount card that customers can use at ...

Drug coupon aggregator GoodRx and pharmacy benefit managers including CVS Caremark and Express Scripts have been hit with at least three class action lawsuits accusing them of working together to ...

Barclays lowered the firm’s price target on GoodRx (GDRX) to $6 from $10 and keeps an Overweight rating on the shares post the Q3 report.

In a report released today, Jailendra Singh from Truist Financial maintained a Hold rating on GoodRx Holdings (GDRX – Research Report), ...

The usual PBM strategy cuts an independent pharmacy's share of the prescription revenue to just 3 cents per pill dispensed, ...

Three independent pharmacies have filed lawsuits accusing GoodRx, which markets a prescription drug discount card, of ...

Independent pharmacies have filed 3 class action lawsuits against GoodRx Holdings and major pharmacy benefit managers (PBMs).

But ondansetron, approved by the US Food and Drug Administration (FDA) in 1991, has been available as a generic since 2007.